Genmab — November 2017
-
-
5 gode artikler (på dansk!) om det sidste inden for myelomatosebehandling. Især den første hvor prof. Abildgaard sammenligner bispecifikke Abs med car-t er interesant. https://www.myelomatose.dk/blog/forskningsnyheder-om-myelomatose-fra-aarets-eha-konference-i-madrid-med-tilladelse-fra-haematologisk-tidsskrift/
-
Regnskabet "burde" - tja - kun kunne give en lille pil op. Stort set som forventet (kald et kedeligt), men vigtigst så afblæser det grundlag for salgsspekulationer. I stedet kom der et par ting at se frem til. Så her lures der på køb som sædvanlig på evt. større fald.
-
Behersket kursreaktion som ventet. Dejligt at investorerne ikke nøjes med at læse overskrifter.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
